Objective: The present study aims to evaluate the anticancer and immunomodulatory activity of both the alcoholic and aqueous extracts of Crateva magna (ALCM and AQCM) in solid tumor model and ascites tumor model in mice.
INTRODUCTION
Cancer is a disease ranked as the second leading cause of morbidity next to cardiovascular diseases [1] . In spite of extensive global research aimed at amending the miserable outcomes of cancer, no apparent decline in the overall mortality rate seen over the past 30 years. From the ancient period, plants are useful in the management of cancer [2] . Over 60% of the presently used anticancer agents obtained in one or the other from natural sources such as plants, marine organisms, and microorganisms [3] . About 13% of all human deaths occurred due to cancer. The American Cancer Society projected that around 7.6 million people die every year due to cancer [4] . Some of the new chemotherapeutic agents that are currently available for use in a clinical setting are plant-based components include Vinca alkaloids, taxane diterpenoids, epipodophyllotoxin ligands, camptothecin, and other derivatives of quinolone alkaloids.
Crateva magna (CM) belonging to the family Capparaceae commonly used in the treatment of urinary disorders that reoccur due to the progress of antibiotic resistance caused by the infecting organism. In traditional medicine, leaves have lithotriptic, diuretic, demulcent, and tonic properties. Externally, the paste of its leaves applied in cervical adenitis, abscess, and edematous wounds. The same adhesive is salutary in the rheumatic joint for relief of pain. In folk medicine, its stem pith used by the tribal people of Kandhamal district of Orissa known as Eastern Ghats of India. The bark of this plant used for lactation after childbirth, treatment of urinary disorders, bladder stones, fever, nausea, and gastrointestinal irritation. Earlier research was done on this plant reports the in vivo sedative and cytotoxic activities of the methanolic extract.
The alcoholic extract decreased the locomotor activity of mice in an elevated plus maze, open field, and hole cross tests. The alcoholic extract exhibited dose-dependent cytotoxicity in brine shrimp lethality assay with an IC 50 of 59.67 µg/ml as compared to 0.45 µg/ml shown by standard vincristine sulfate [5] evaluated the bark of the plant for its antipyretic activity on TAB-VACCINE induced pyrexia in rabbits. The alcoholic extract of aerial parts of CM formed a significant decrease in the body temperature in hyperthermic rats. Remya et al. (2009) investigated the entire plant for the treatment of benign prostatic hyperplasia. Alam et al. (2006) evaluated the crude extract of leaves of CM for its antinociceptive activity in mice. The "acetic acid" analgesic test method in mice was used to assess the antinociceptive effect. Crude ethanolic extracts of CM (250-500 mg/kg PO) showed dose-dependent, antinociceptive effect against chemically induced nociceptive pain stimuli in mice. In vivo and in vitro antitumor activity of leaves of CM has not reported so far. Hence, the current study emphases the antitumor activity of ethanolic and aqueous extract of the CM.
MATERIALS AND METHODS

Materials
Plant material and extraction
The plant material (fresh leaves of CM) was procured from Natural Remedies Pvt. Ltd., Bengaluru and was authenticated by Dr. M. N. Naganandini, Department of Pharmacognosy, JSS College of Pharmacy, Mysuru, India. The coarse powder was extracted with 95% ethanol in the Soxhlet extractor. The residue was dried over a water bath to obtain the alcoholic extract of CM (ALCM). The aqueous extract was prepared by cold maceration method. After completion of extraction, the marc was filtered through muslin cloth followed by filter paper and concentrated and dried on a water bath to obtain the aqueous extract of CM (AQCM).
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Cell lines
Dalton's Lymphoma ascites (DLA) and Ehrlich Ascites Carcinoma (EAC) cell lines were procured from Amala Cancer Research Center, Thrissur, India.
Animals
All the animal experiments and handling of animals were approved by the Institutional Animal Ethics Committee (IAEC), JSS College of Pharmacy, Mysuru, India (IAEC approval number 134/2013). Swiss albino mice of eight to 10 weeks old weighing between 25 and 30 g were selected for the study. Animals were acclimatized to the experimental room for 1 week before the experiment. Animals were maintained under controlled conditions of temperature (27±2°C) and were caged in sterile polypropylene cages containing sterile paddy husk as bedding material with a maximum of six animals in each cage. The mice were fed on a standard diet and water ad libitum.
Methods
In vitro antioxidant activity using mice α, α-Diphenyl-β-picrylhydrazyl (DPPH) free radical scavenging assay 2 ml of 0.1 mM of DPPH was added to 2 ml of methanol. The absorbance was taken immediately, at a wavelength of 517 nm, which serves as a control. 2 ml of DPPH was added to 2 ml of test extracts (ALCM and AQCM) and shaken well. The test samples were incubated for 30 min. The absorbance was recorded against methanol as blank at a wavelength of 517 nm [6] . The % scavenging activity and IC 50 was determined [7] .
− =
Absorbance of control Absorbance of test %scavengingactivity
Absorbance of control 3-Ethylbenzothiazoline-6-sulfonic acid (ABTS) -decolorizing assay Different concentrations of test extracts (ALCM and AQCM) (50, 100, 150, 200, 250, and 300 µg/ml) were reacted with 5 ml of fresh ABTS •+ solution.
Absorbance was measured against blank after 15 min of incubation in the dark at 734 nm. L-Ascorbic acids were used as a standard. The % scavenging activity was determined, and IC 50 was calculated [8] .
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Reducing power assay 1 ml of different concentrations of the sample (20, 40, 60, 80, and 100 µg/ml) were assorted with 2.5 ml of phosphate-buffered saline (PBS) (0.2 M, pH 7.6) and 2.5 ml of potassium ferricyanide (1% W/V). The combined solution was incubated at 50°C for 30 min. 2.5 ml of trichloroacetic acid (TCA) (10% W/V) was added to the mixture, which was then centrifuged at 3000 rpm for 10 min [9] . 2.5 ml of the upper layer of the solution was mixed with 2.5 ml of distilled water and 0.5 ml of FeCl 3 (0.1% W/V), the absorbance was measured against blank at 700 nm.
In vitro cytotoxic activity
Trypan blue exclusion assay EAC and DLA cells were aspirated from the peritoneal cavity of tumorbearing mice. Two to three times, the cells were washed with PBS, and one million cells were incubated with different concentrations of ALCM and AQCM (20, 40, 60, 80, and 100 µg/ml) [10] . Cyclophosphamide (50 µg/ml) alone in a volume of 0. 
Brine shrimp lethality assay
The test extracts of ALCM and AQCM were prepared using seawater. Ten Nauplii were transferred into sample vials and were treated with different concentrations of test compounds (100, 200, 300, 400, and 500) micromolar in 5 ml of seawater for 24 h. A drop of the suspension was added to each vial. Vials were maintained under illumination. After 24 h, the number of surviving Nauplli was counted using ×3 magnifying glass, and the percentage cytotoxicity and IC 50 values were determined [12] . In vivo antitumor activity of ALCM and AQCM against EAC inoculated ascites tumor model EAC cells were procured from the peritoneal cavity of an EAC bearing mouse, after 15 days of tumor transplantation. The ascitic fluid was withdrawn and suitably diluted in phosphate buffer saline to obtain a stock cell concentration of 10 7 cells per ml. For ascitic tumor 2.5×10 6 , EAC cells (0.25 ml of stock suspension) were injected intraperitoneally to each mouse [13] . Treatment was started after 24 h of tumor inoculation and was continued for 15 days, and the various parameter was evaluated [14] :
% Increase in body weight as compared to "0" day weight
The animals were weighed on the day of inoculation and once in 3 days after that in the post-inoculation period. The % increase in body weight was calculated as follows [15] : − = × (Animal weight on a respected day) 1 % increase in weight 100 Weight of animal on day 0
Mean survival time (MST) and percentage increase in life span (%ILS)
A total number of days an animal survived from the day of tumor inoculation were counted. Subsequently, the MST was calculated. The %ILS was calculated as:
Mean survival time concentration]) % increase in life span 100 Mean survival time concentration
Hematological parameters
To assess the hematological status of treated animals, blood was withdrawn from retro-orbital plexus of the animals. The collected blood was transferred into sodium citrate treated microcentrifuge tubes, and the following parameters were monitored [16] .
Determination of total white blood cell (WBC) count
Blood was drawn up to 0.5 marks of WBC pipette, and excess of blood from the tip was wiped off. The collected blood was diluted with WBC diluting fluid (1% acetic acid, 1 ml glacial acetic acid was added to 99 ml distilled water) up to mark 11 and was mixed thoroughly for 1 min. The fluid was charged on the counting chamber of hemocytometer. The total number of cells in all the four corner squares of WBC counting area was counted using ×10 objective. Then, the total WBC count was calculated from the number of cells/mm using the formula:
Total WBC count = Total number of cells in the WBC counting area×50
Determination of total red blood cell (RBC) count
Blood was drawn up to 0.5 marks of RBC pipette, and the excess of blood was wiped off from the tip. Then, the pipette was filled to 101 marks with RBC diluting fluid and mixed thoroughly for 1 min. The fluid was charged on the counting chamber of hemocytometer. The total number of cells in the RBC counting area was counted using ×45 objective. The average number of cells/mm 3 was calculated using the formula:
Total RBC count = Total number of cells in the RBC counting area×1000
Where 1000 is the volume of RBC counting area.
Estimation of serum biomarkers
Estimation of serum glutamic oxaloacetic transaminase (SGOT)
Four volumes of reagent-1 (TRIS, L-Aspartate, malate dehydrogenase, and lactate dehydrogenase [LDH]) were mixed with one volume of
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reagent-2 (alpha-ketoglutarate, NADH). These two reagents were mixed and incubated for 1 min at 37°C. Absorbance was measured after 1 min using Merck Semi Auto Analyzer [17] .
Estimation of serum glutamic pyruvate transaminase (SGPT)
The 1000 µl of a working solution consisting of Tris buffer, L-alanine, LDH, α-ketoglutarate, and NADH and 10 µl of sample solution were mixed and incubated for 1 min. Absorbance was read after 1 min using Merck Semi Auto Analyzer.
Estimation of Alkaline phosphatase (ALP)
Four volumes of reagent-1 (diethanolamine, and magnesium chloride) were mixed with one volume of reagent-2 (p-Nitrophenyl phosphate). The 500 µl of working solution and 10 µl of sample solution were incubated for 50 s, and absorbance was read using semi auto analyzer.
Estimation of LDH
Four volumes of reagent-1 (imidazole pyruvate-65mmol/L) were mixed with one volume of Reagent-1 (NADH-0.18 mmol/L) and were incubated. 3.0 µL of working sample and 50 µL of sample solution were incubated. Then, the initial absorbance of the sample was measured. The absorbance was read at the 1-min interval and for 3 min after that. The difference between the absorbance and the average absorbance per minute was calculated (ΔA/min).
Estimation of liver endogenous antioxidant enzymes
3 ml of hydrogen peroxide phosphate buffer solution was added to 50 μl of tissue homogenate, and absorbance was measured at 240 nm [18] .
Estimation of glutathione-S-transferase (GSH)
500 µL of TCA solution was added to 500 µl of tissue homogenate, and then it was centrifuged. 500 µl of supernatant was incubated with 3 ml of PBS and 500 µL DTNB for 10 min at room temperature. Absorbance was read at 412 nm against blank, and glutathione concentration was calculated.
Estimation of superoxide dismutase (SOD)
1850 µL of carbonate buffer 0.1 M was added to 50 µl of tissue homogenate. 100 µl of adrenaline was added directly in cuvette after putting in ultraviolet cuvette holder, absorbance was read at 480 nm (A0-A60) (Kinetic method).
DNA fragmentation assay
A DNA ladder represents a band of DNA molecules of varying lengths separated in agarose gel by electrophoresis. Agarose was added to electrophoresis buffer to prepare gel. The solution was placed in a microwave oven until the agarose particles were liquefied. The molten agarose was cooled, and ethidium bromide was added, and the gel was prepared. A fixed number of cells were treated with different concentration fractions, vehicle control, and standard for 48 h. Cells were then collected, centrifuged, and lysis buffer was added to the cell pellet. Cell pellet in lysis buffer was incubated for 1 h with RNAse solution for 1 h. The processed cells were cooled and loaded into wells of agarose gel followed by electrophoresis. Images were taken using a gel documentation system [19] .
In vivo antitumor activity of ALCM and AQCM against DLA inoculated tumor model
After 15 days of tumor transplantation, the DLA cells were aspirated from the peritoneal cavity of DLA bearing mice. Tumor viability was determined by Trypan blue exclusion test, and a total number of viable cells were counted using hemocytometer. The ascitic fluid was appropriately diluted in saline to get a concentration of 10 7 cells/ml of tumor cell suspension. Around 0.1 ml of this solution was injected subcutaneously to the right hind limb of mice to obtain a solid tumor. After 24 h tumor inoculation, the treatment was started and was continued for 15 days, tumor volume, and tumor weight was assessed [20] .
Tumor volume
Vernier caliper was used to measure the radii of developing tumor at 5 days interval for 1 month, and tumor volume was calculated using the formula: V = 4/3π dc 2 Where c and d represent the major and minor radii.
Tumor weight
Animals were sacrificed at the end of the 4 th week under anesthesia using diethyl ether; the tumor was extirpated and weighed. The percentage inhibition was calculated by the formula:
Where C is the average tumor weight of control group, D is that of the treated group.
In vivo immunomodulatory activity
Carbon clearance test
Swiss albino mice of 25-30 g of body weight were used in the experiment. Animals were randomized into the following six groups comprising six animals each. Animals were given the test extracts for 2 days. The mice were administered with carbon ink suspension through tail vein after 48 h of intraperitoneal injection. Blood samples were collected from the retro-orbital vein using glass capillaries at 5 min and 15 min [21] . Collected blood samples were mixed with 0.1% sodium carbonate solution for the lysis of erythrocytes. Absorbance was measured using the spectrophotometer at 675 nm. The phagocytic activity was expressed by the phagocytic index (K) [22] .
Where, OD 1 and OD 2 are optical densities at time t 1 and t 2 .
The clearance rate is expressed as the half-life period of carbon ink in the blood. t½ = 0.693/K
Delayed type hypersensitivity
Daily treatment of test extracts was given to the mice 5 days before the challenge. Control received the vehicle on each day. On day 0, all animals were immunized with 20 µl of sheep RBC (SRBC) solution (5×10 9 SRBC/ml) injected subcutaneously into their right hind footpad. After 5 days of treatment, the thickness of each animal's footpad was measured just before the challenge using a digital plethysmometer. The animals were then challenged by injecting the 20µl of SRBC solution into the left hind footpad (deemed time 0). Foot thickness was remeasured after 24 h [23] . The difference between the thickness of left foot just before and after challenge (in mm) was taken as the measure of DTH. − = × SRBC treatment paw saline treated paw DTH response 100 SRBC treated paw
Statistical analysis
All experiments were done in triplicate, and values were reported as mean±standard error of the mean. Statistical analysis was by one-way ANOVA followed post hoc Tukey's multiple comparison analysis. The level of significance was set up at p<0.05.
RESULTS
DPPH-free radical scavenging assay
Both extracts of ALCM and AQCM exhibited dose-dependent free radical scavenging activity. The IC 50 of AQCM and ALCM was found to be 89.75±0.001 µg/ml and 55.97±0.002 µg/ml, respectively, when compared to ascorbic acid with an IC 50 of 3.6±0.001 µg/ml which are shown in Fig. 1 .
ABTS-decolorizing assay
Both the extracts ALCM and AQCM exhibited dose-dependent free radical scavenging activity. The IC 50 of AQCM and ALCM was found
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to be 268.70±0.5 µg/ml and 270.07±0.38 µg/ml, respectively, when compared to ascorbic acid with an IC 50 of 22.16±0.4 µg/ml, as shown in Fig. 2 .
Reducing power assay
Reducing power assay of ALCM and AQCM is shown in Fig. 3 :
Trypan blue exclusion assay
In vitro cytotoxicity of extracts, ALCM and AQCM on EAC cells were determined by Trypan blue exclusion assay. Both the extracts showed dose-dependent cytotoxicity with an IC 50 of 298±0.50 and 356±0.62 µg/ml, respectively. The percentage cytotoxicity of ALCM and AQCM on EAC cells by Trypan blue exclusion assay is shown in Fig. 4 . 
Fig. 4: Percentage cytotoxicity of alcoholic extracts of Crateva magna (CM) and aqueous extracts of CM on Ehrlich Ascites Carcinoma cells by Trypan blue exclusion assay. All values are expressed as mean±standard error of the mean, n=3
Brine shrimp lethality assay
Brine shrimp lethality assay was carried out on both the extracts. ALCM and AQCM showed dose-dependent cytotoxicity with an IC 50 of 88.74±0.62 and 119.68±0.82 µg/ml, respectively. The percentage lethality of ALCM and AQCM by brine shrimp lethality assay is shown in Fig. 5 .
Effect of AQCM and ALCM on body weight changes
Substantial increase in body weight was seen in EAC inoculated control animals with a maximum growth of 75.0±4.5% on day 15 compared to day 0. The cyclophosphamide treatment significantly reduced body weight (18.67±3.6%) compared to control. ALCM treatment at 200 mg/kg significantly decreased the tumor-induced percentage increase in the body weight (37.19±1.1%), and the efficacy was compared with standard. The effect of ALCM and AQCM on body weight changes in EAC inoculated animals is shown in Fig. 6 . 
Effect of ALCM and AQCM on MST and % increase in the life span of EAC inoculated mice
Effect of ALCM and AQCM on hematological parameters in EAC inoculated mice
To assess the influence of ALCM and AQCM treatment on hematological parameters, the total RCBs, WBCs, and hemoglobin content of all the treatment groups were checked on the 15 th day of tumor inoculation.
Effect on total WBC
A significant rise in total WBC count was seen in EAC inoculated control animal (20.63±0.91 cells/mm 3 ) when compared to the normal animal (7.01±0.53 cells/mm 3 ). Standard cyclophosphamide treatment at a dose of 10 mg/kg resulted in a reduction in the WBC count to (6.05±0.86 cells/mm 3 ) when compared with control. ALCM at dose 100 mg/kg and 200 mg/kg significantly reversed the elevated WBC to 11.67±0.69 cells/mm 3 and 13.72±0.63 cells/mm 3 when compared to control.
Total RBC
A significant decrease in total RBC count was seen in EAC inoculated control animal (2.84±0.05 cells/mm 3 ) when compared with the normal mice (5.53±0.34 cells/mm 3 ). Treatment with cyclophosphamide 10 mg/kg significantly reversed this reduction to 5.16±0.09 cells/mm 3 as compared to control; and ALCM at 100 mg/kg doses increased the total RBC count to 3.51±0.81 and 4.08±0.19 cells/mm 3 when compared to control animal.
Effect of ALCM and AQCM on serum enzyme levels
To assess the influence of ALCM and AQCM treatment on serum enzyme levels, the ALP, SGOT, and SGPT of all the treatment groups were checked on the 15 th day of tumor inoculation.
Effect on serum glutamic oxaloacetic transaminase (SGOT)
A 
Evaluation of liver endogenous antioxidant enzymes
To assess the influence of ALCM and AQCM treatment on endogenous liver antioxidant levels, all the treatment groups were checked on the 15 th day of tumor inoculation.
Effect of GSH
A significant decrease of GSH concentration was observed in liver homogenate of ECA inoculated control mice 0.850±0.15 mg/kg when compared to normal animal 2.950±0.35 mg/kg. Cyclophosphamide at a dose of 10 mg/kg significantly reversed the tumor-induced decrease in GSH concentration 1.78±0.15 mg/kg when compared with control. ALCM at 200 mg/kg significantly reversed GSH concentration to 1.574±0.2305 mg/kg, and the efficacy was compared with the standard group.
Effect of SOD
A significant decrease in SOD concentration was observed in liver homogenate of EAC inoculated control mice 2.28±0.25 mg/kg when compared to normal animal 4.54±0.25 mg/kg. Standard cyclophosphamide treatment at 10 mg/kg dose significantly reversed the tumor-induced decrease in SOD concentration 3.92±0.155 mg/kg when compared with control. ALCM at 200 mg/kg reversed GSH concentration to 3.09±0.25 mg/kg significantly in treated animals, the efficacy was compared with the standard group.
Influence of extracts on DNA fragmentation assay
The effect of extracts on DNA fragmentation assay is shown in Fig. 7 :
In vivo anticancer activity of ALCM and AQCM on DLA inoculated solid tumor model
The weight of solid tumor in the control animal was found to be 6.85±0.226 g by the end of the 4 th week. Cyclophosphamide at 10 mg/kg dose showed a significant reduction in the solid tumor weight by 85.76±1.02 g when compared to control. ALCM and AQCM at the dose of 200 mg/kg caused a significant reduction in the solid tumor weight when compared with control. ALCM at a dose of 200 mg/kg was more effective in reducing the tumor weight by 54.02±6.3%, the extent of tumor growth inhibition was not comparable to standard.
Carbon clearance test
There was an increased clearance of carbon particles from blood after administration of ALCM at 100 mg/kg and 200 mg/kg p.o. It is specified by a significant rise in the phagocytic index when compared to the control group. The effect of ALCM and AQCM on the phagocytic index is shown in Fig. 8 . is shown in Fig. 9 . 39.92±4.01% increase in paw volume, which was significant when compared to control. The effect of ALCM and AQCM on the paw volume in mice is shown in Fig. 9 .
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Delayed-type hypersensitivity
DISCUSSION
The current study was designed to explore the possible antitumor activity of CM in transplantable tumor models. The research involves DLA induced and EAC induced ascites robust tumor model. Based on encouraging results, both the extracts in vitro antioxidant assays and preliminary cytotoxic assay were proceeded further for investigating the antitumor potential in transplantable tumor models. Ascites tumor model is a type of rapidly growing carcinoma, which is inoculated in the outbred mice by serial intraperitoneal transplantation. Ascites fluid was aspirated from the tumor-bearing mice and injected to the normal mice. On 15 th day there was substantial increase in body weight of tumor control group animals. The maximum increment in the body weight was 75.0 g in mice bearing tumor. Treatment by ALCM and AQCM at the dose of 200 mg/kg substantially decreased the bodyweight to 37.1 g and 40.6 g. It is quite evident that ALCM demonstrated more significant activity when compared to AQCM. MST enhanced by ALCM treatment at a dose of 200 mg/kg. The life span was increased up to 31.87% by ALCM at a dose of 200 mg/kg. AQCM 200 mg/kg also enhanced the survival time up to 27.47%. %ILS by 25% or more when compared to control is considered as an effective anticancer response. Both the extracts showed the enhancement in the life span, more than that of control. The influence of tumor growth on hematological and biochemical parameters is well established; hence, to assess the influence of ALCM and AQCM on the hematological parameters, the total RBC count, WBC count, and hemoglobin content of all the treated groups were checked on 15 th day of tumor inoculation.
In tumor control animals, there was a significant rise in the WBC count. Treatment with ALCM and AQCM at 200 mg/kg dose reversed the enhanced WBC count in the treated group, which was more significant to that of control. Standard cyclophosphamide at 10 mg/kg dose decreased the cell count than the normal reflecting myelosuppression. There was a decrease in RBC count in the control group, which was restored by the treatment of ALCM and AQCM at 200 mg/kg dose. Ascites tumor-bearing mice reduced the hemoglobin content, which is a hallmark in iron deficiency. The therapy with ALCM and AQCM at 200 mg/kg reversed the tumor-induced alternation in hematological parameters.
CONCLUSION
The present study indicated that ALCM extract exhibited more antioxidant potential by well-established methods. Both the extracts of CM were assessed for their in vivo antitumor activity in both EAC and DLA transplantable tumor-bearing animals. Both the extracts reflected their cytotoxic potential as evident in vitro cytotoxicity assays such as brine shrimp lethality assay and Trypan blue cytotoxicity assay. ALCM exhibited more potent cytotoxicity as compared to AQCM. In the EAC model, ALCM showed a reduction in increased body weight, as well as an increment in the survival time, which indicates inhibition in the tumor progression. The alcoholic extract at the dose of 200 mg/kg body weight reversed the hematological parameters and restored the endogenous antioxidant and serum enzymes, which signed with that of control. In DLA model, ALCM at the doses 100 mg/kg and 200 mg/kg decreased the growth of the solid tumor as evidenced by the reduction of solid tumor weight and volume when compared with control. Both the extracts evaluated for their immunomodulatory activity in vivo. ALCM and AQCM screened for immunomodulatory models such as carbon clearance test and delayed-type hypersensitivity. ALCM exhibited low phagocytic index compared to the standard, which indicates its ability to enhance the carbon clearance rate. SRBC-induced delayed-type hypersensitivity was used to assess the effect of the extract on cell-mediated immunity. ALCM exhibited much reduction in the paw edema as compared to control. Therefore, the increase in DTH reaction to cell-dependent antigen showed the inhibitory effect of ALCM.
